Nkarta to Participate in an April Investor Conference
Nkarta (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.
The company will engage in a fireside chat scheduled for April 8, 2025, at 11:00 a.m. ET. Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website. The presentation recording will remain available on www.nkartatx.com for approximately 90 days following the event.
Nkarta (Nasdaq: NKTX), una compagnia biofarmaceutica specializzata in terapie con cellule natural killer (NK) ingegnerizzate, ha annunciato la sua prossima partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
L'azienda parteciperà a una chiacchierata informale programmata per l'8 aprile 2025, alle 11:00 ET. Gli investitori e le parti interessate possono accedere a una diretta dell'evento attraverso la sezione Investitori del sito web di Nkarta. La registrazione della presentazione rimarrà disponibile su www.nkartatx.com per circa 90 giorni dopo l'evento.
Nkarta (Nasdaq: NKTX), una empresa biofarmacéutica especializada en terapias con células asesinas naturales (NK) ingenierizadas, ha anunciado su próxima participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
La compañía participará en una charla informal programada para el 8 de abril de 2025, a las 11:00 a.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo del evento a través de la sección de Inversores en el sito web de Nkarta. La grabación de la presentación estará disponible en www.nkartatx.com durante aproximadamente 90 días después del evento.
Nkarta (Nasdaq: NKTX), 엔지니어링된 자연 살해 세포(NK) 치료를 전문으로 하는 생명공학 회사가 제24회 니덤 가상 의료 회의에 참석할 예정이라고 발표했습니다.
회사는 2025년 4월 8일 오전 11시 ET에 예정된 대화에 참여할 것입니다. 투자자 및 관심 있는 당사자는 Nkarta 웹사이트의 투자자 섹션을 통해 이벤트의 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 약 90일 동안 www.nkartatx.com에서 이용 가능합니다.
Nkarta (Nasdaq: NKTX), une entreprise biopharmaceutique spécialisée dans les thérapies par cellules tueuses naturelles (NK) ingénierées, a annoncé sa prochaine participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
L'entreprise participera à une discussion informelle prévue pour le 8 avril 2025 à 11h00 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de l'événement via la section Investisseurs du site web de Nkarta. L'enregistrement de la présentation restera disponible sur www.nkartatx.com pendant environ 90 jours après l'événement.
Nkarta (Nasdaq: NKTX), ein biopharmazeutisches Unternehmen, das auf ingenieurtechnisch entwickelte natürliche Killerzellen (NK) spezialisiert ist, hat seine bevorstehende Teilnahme an der 24. jährlichen virtuellen Needham Gesundheitskonferenz angekündigt.
Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für den 8. April 2025 um 11:00 Uhr ET geplant ist. Investoren und interessierte Parteien können über den Bereich Investoren auf der Website von Nkarta auf einen Live-Stream der Veranstaltung zugreifen. Die Aufzeichnung der Präsentation wird für etwa 90 Tage nach der Veranstaltung auf www.nkartatx.com verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
| 24th Annual Needham Virtual Healthcare Conference |
| April 8, 2025 |
| 11:00 a.m. ET – fireside chat |
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com
FAQ
When is Nkarta (NKTX) presenting at the Needham Healthcare Conference 2025?
How can investors watch Nkarta's (NKTX) Needham Conference presentation?
How long will Nkarta's (NKTX) Needham Conference presentation be available for replay?
What type of therapies does Nkarta (NKTX) develop?
